Drugs / CVD 1208S-122
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04634513 | Sep 2022 → Oct 2024 | escherichia coli infection, shigellosis | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVD 1208S-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634513 ↗ |
| Modality | Vaccine | “combined Shigella-ETEC vaccine candidate” NCT04634513 ↗ |
| Route | Oral | “single, oral dose” NCT04634513 ↗ |